Topiramate in frontal lobe epilepsy

Acta Neurol Scand. 2007 Feb;115(2):132-5. doi: 10.1111/j.1600-0404.2006.00758.x.

Abstract

Background: Frontal lobe epilepsy (FLE) is a type of epilepsy that is difficult to treat and there are few studies about the use of topiramate (TPM).

Aim of the study: To evaluate the efficacy and tolerability of TPM monotherapy in FLE.

Methods: The study group consisted of 55 (33 male; 22 female) patients. TPM was administered as a first drug (n = 16) or converted after previous treatment (n = 39). All patients were followed every 3 months for at least 1 year. The patients were subdivided into two groups: 'newly diagnosed' patients and 'difficult-to-treat' patients.

Results: Overall, all patients completed the 1-year study. At the end of follow-up, 10 patients showed disappearance of seizures and 33 patients showed improvement in seizure frequency. In particular, among the newly diagnosed patients 6/16 patients showed complete cessation of seizures and 5/16 patients showed very good response; in the other group, 4/39 patients showed complete cessation and 4/39 patients showed a very good response. No patients of both groups had worsening of seizures. No treatment-limiting adverse events associated with TPM were reported.

Conclusions: TPM is effective in newly diagnosed patients with FLE; TPM can be considered for the treatment of FLE.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use*
  • Child
  • Child, Preschool
  • Epilepsy, Frontal Lobe / drug therapy*
  • Female
  • Follow-Up Studies
  • Fructose / adverse effects
  • Fructose / analogs & derivatives*
  • Fructose / therapeutic use
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Patient Compliance
  • Retrospective Studies
  • Topiramate
  • Treatment Outcome

Substances

  • Anticonvulsants
  • Topiramate
  • Fructose